Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › multiple system atrophy

Multiple system atrophy

Part of Movement Disorders

4 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for multiple system atrophy

13 trials tracked for multiple system atrophy: 3 in phase 3 or 4 and 2 with published results. The most-cited published study has 85 citations.

13Trials tracked
3Phase 3 & 4
0Recruiting
2With published results
Phase distribution
Phase 3 3 Phase 2 6 Other / NA 4
  1. Phase 3 Study of BHV-3241 in Participants With Multiple System Atrophy Completed · 85 cited
  2. Phase 3 Progression Rate of MSA Under EGCG Supplementation as Anti-Aggregation-Approach Completed
  3. Phase 3 Open-Label Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH) Completed
  4. Phase 2 Treatment of Multiple System Atrophy Using Intravenous Immunoglobulins Completed
  5. Phase 2 Safinamide for Multiple System Atrophy (MSA) Completed
  6. Phase 2 A Study of TAK-341 in Treatment of Multiple System Atrophy Completed
Show 7 more trials
  1. Phase 2 Clinical Trial to Assess Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients With Multiple System Atrophy of the Parkinsonian Subtype (MSA-P) Completed
  2. Phase 2 Exenatide Once-weekly as a Treatment for Multiple System Atrophy Completed
  3. Phase 2 Treatment of Parkinson Disease and Multiple System Atrophy Using Intranasal Insulin. Completed
  4. N/A Local Heat Stress in Autonomic Failure Patients With Supine Hypertension Completed
  5. N/A Nebivolol in the Supine Hypertension of Autonomic Failure Completed
  6. N/A In-Home Care for Patients With PSP and Related Disorders Completed
  7. N/A Rehabilitative Trial With Cerebello-Spinal tDCS in Neurodegenerative Ataxia Completed

Showing the 13 most-cited and recently-updated of 13 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
QSM MRI reveals distinct iron deposition patterns differentiating Parkinsonian syndromes
Neurology Meta-analysis
QSM MRI reveals distinct iron deposition patterns differentiating Parkinsonian syndromes Brain MRI technique may help tell apart Parkinson's and similar disorders
This systematic review and meta-analysis of 626 PD, 160 MSA, 176 PSP patients and 256 controls found that quantitative susceptibility mappin…
A special MRI can spot distinct brain iron patterns in Parkinson's and related diseases, offering a potential diagnostic tool.
Jun 1, 2026
Cross-sectional survey reveals high rates of undiagnosed neurogenic orthostatic hypotension in multiple system atrophy patients
Neurology
Cross-sectional survey reveals high rates of undiagnosed neurogenic orthostatic hypotension in multiple system atrophy patients Blood Pressure Drops Are Leaving MSA Patients Unable to Stand—And Often Overlooked
This cross-sectional survey of 259 community-based patients with multiple system atrophy (MSA) examines the prevalence of neurogenic orthost…
This study reveals that most MSA patients suffer from undiagnosed blood pressure drops that make daily tasks nearly impossible, even with me…
medRxiv Apr 22, 2026
Observational review of phenoconversion rates and biomarker alignment in Parkinson's disease genetic cohorts
Neurology
Observational review of phenoconversion rates and biomarker alignment in Parkinson's disease genetic cohorts Do your symptoms match the biology, or is the disease hiding in plain sight?
This observational cohort analysis reviews phenoconversion rates and biomarker alignment in Parkinson's Progression Markers Initiative parti…
In people at genetic risk for Parkinson's, symptoms and biological markers often don't align, with nearly one-third showing advanced brain c…
medRxiv Apr 20, 2026
6-metabolite blood biomarkers aid differential diagnosis of Parkinson's disease versus healthy controls and other neurodegenerative conditions
Neurology
6-metabolite blood biomarkers aid differential diagnosis of Parkinson's disease versus healthy controls and other neurodegenerative conditions Can a simple blood test tell the difference between Parkinson's and other brain diseases?
This observational study assessed a 6-metabolite blood biomarker (6M-BB) profiled by 1H NMR for distinguishing Parkinson's disease (PD) from…
A simple blood test using six metabolites correctly identified Parkinson's disease in nearly 95% of cases while distinguishing it from other…
medRxiv Apr 9, 2026